HealthMed Services Ltd. (OTC:HEME), an innovative software development company, is pleased to announce that it has entered final negotiations to acquire all rights, title and interest to Neural Communicator software and hardware. Neural Communicator has developed brain/computer interface devices and software designed to enable people with extreme disabilities to communicate. The device detects eye movement, jaw contractions and ALPHA and BETA brain waves allowing hands free input.
HEME has also entered into an agreement with a European Research and Development Company to develop, test and market a specialty healthcare communication product, namely Neural Vantage.
Healthmed and its software developers are now beta testing the communicator.
The revolutionary product will target people with disabilities such as amputation and paralysis due to the fact that these types of illnesses prevent them from communicating with ease.
HEME has created a platform where information from the patients body can be entered to a computer through the use of biotechnology. This new technology is called BCI for Brain Computer Interface.
The software and interface is password protected with end-to-end user authentication. All data is protected with AES encryption using 128-bit keys.
It will automatically update of both parts of software, computer and iPad.
View your computer desktop in true 24-bit color.
You will be able to hear sound from your computer on your iPad.
You can record or transmit sound with your iPad to your computer.
Your computer can have multiple monitors. Each monitor can be remotely controlled.
You may invite guests to share your computer from other iPads.
HealthMed also plans to provide online services through its Web site that includes a public portal, a Web site for individuals, consumers, and the general public that is designed to provide health information and recommendations; and a private and custom-designed/client-specific portal, a private-labeled Web site that would allow employees to access their personal health records and research various health and medical related topics, as well as provide access to information and resources to assist them in making personal health plan and medical treatment decisions.
You may read more about HEME and its product developments on its website: www.healthmedltd.com
Generex Biotechnology Corporation (Nasdaq:GNBT)
Generex Biotech is the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has created a scientific advisory board in an effort to further its drug development programs, specifically in the areas of oncology and metabolic diseases.
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today it has initiated an integrated Social Media campaign across its corporate website as well as its e-commerce websites for its various consumer diet, glucose raising and energy products, including Glucose RapidSpray(TM), Crave-NX(TM) Diet Spray, BaBoom!(TM) Energy Spray and Glucose RapidSpray(TM) for Pets(TM). Through Facebook, Twitter and various other online community destinations, these social media campaigns serve to increase brand awareness, build online community engagement and enhance long-term customer loyalty via relevant content postings and on-demand conversations.
We are excited about utilizing the social media campaign to introduce and communicate about our products and platforms within the vast online media landscape, said Rose C. Perri, Generexs Chief Operating Officer. We consider this type of service as having a growing role in the future of patient, customer and investor communications.
EpiCept Corporation (Nasdaq:EPCT) has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene (histamine dihydrochloride). Ceplene is EpiCepts novel therapeutic candidate for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission, which was approved in the European Union in 2008 and is co-administered with low-dose interleukin-2 (IL-2).
In its preliminary review of the Ceplene NDA, the FDA concluded that the application did not establish Ceplenes therapeutic contribution in its combination with IL-2, and recommended that an additional confirmatory pivotal trial assessing Ceplenes contribution and using overall survival as a primary endpoint be conducted.
EpiCept intends to request a meeting with the FDA as soon as possible to discuss its comments on the NDA submission. The Company retains the right to file the NDA over FDA objections.
EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Companys lead product is Ceplene, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars in cash from a third party (Media Elite Consultants LLC) for (1) day of advertising for Healthmed Services Ltd. (OTC BB: HEME.OB)
About the Author: